双环胺AMD3100的故事。

The bicyclam AMD3100 story.

作者信息

De Clercq Erik

机构信息

Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium.

出版信息

Nat Rev Drug Discov. 2003 Jul;2(7):581-7. doi: 10.1038/nrd1134.

DOI:10.1038/nrd1134

PMID:12815382

Abstract

The discovery and development of the bicyclam AMD3100--a chemokine receptor antagonist--has highlighted the therapeutic potential of such compounds in HIV infection, inflammatory diseases, cancer and stem-cell mobilization. Here, I describe the development process of AMD3100, which began about 15 years ago with the isolation of an impurity, and the basis for the clinical application of AMD3100 and its congeners.

摘要

双环胺AMD3100（一种趋化因子受体拮抗剂）的发现与研发，凸显了此类化合物在治疗HIV感染、炎症性疾病、癌症及干细胞动员方面的潜力。在此，我将描述AMD3100的研发过程（该过程始于约15年前一种杂质的分离）以及AMD3100及其同类物临床应用的依据。